, Tracking Stock Market Picks
Enter Symbol:
Synergy Pharmaceuticals Inc (SGYP) [hlAlert]

up 146.82 %

Synergy Pharmaceuticals Inc (SGYP) rated Buy with price target $9.50 by ROTH Capital

Posted on: Thursday,  Oct 29, 2015  8:25 AM ET by Roth Capital

Roth Capital rated Buy Synergy Pharmaceuticals Inc (NASDAQ: SGYP) on 10/29/2015. Previously Roth Capital rated Buy Synergy Pharmaceuticals Inc (NASDAQ: SGYP) on
11/18/2014., when the stock price was $2.99. Since then, Synergy Pharmaceuticals Inc has gained 146.82% as of 01/05/2016's recent price of $7.38.
If you would have followed the previous Roth Capital's recommendation on SGYP, you would have gained 146.82% of your investment in 413 days.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company?s lead drug candidate is SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). SP-304 is an analog of uroguanylin, a natural GI hormone secreted in the gut, which is a key regulator of intestinal function. As of December 31, 2009, the Company was developing SP-304, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. SP-304 is an agonist of GC-C. In February, 2010, a Phase IIa 14-day, repeated-oral-dose trial of SP-304 in CC patients opened for enrollment and was actively recruiting patients.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/29/2015 8:25 AM Buy
6.31 9.50
as of 8/27/2015
1 Week down  -8.09 %
1 Month down  -9.11 %
3 Months up  112.06 %
1 YTD up  146.82 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/18/2014 3:25 PM Buy
2.99 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy